Von Willebrand Disease: Bridging the Evidence Gap with a Call to Action for Equitable Care
Nathan Connell, Hematologist at Harvard Medical School, shared a post on LinkedIn:
“Thank you to Drs. Kelsey Uminski, Paula James, and Roy Khalife for asking me to join them in preparing this commentary in Haemophilia Journal, “Bridging the Evidence Gap in von Willebrand Disease: A Call to Action for Equitable, Evidence-Based Care.”
For decades, von Willebrand disease (VWD), the most common inherited bleeding disorder, has been under-researched compared to hemophilia. This evidence gap has led to significant challenges in patient care, including clinical uncertainties and wide variability in practice. This paper outlines why this gap exists and presents a coordinated, five-point research agenda to help close it:
▪️Patient-Centered Trial Design: Shifting away from endpoints that don’t capture the full impact of VWD and focusing on what matters most to patients, like the effect on quality of life.
▪️Adoption of Core Outcome Sets: Standardizing key outcomes to make research more comparable and clinically applicable.
▪️PK-Guided Therapy: Developing accessible tools for individualized, precise dosing, similar to what has revolutionized hemophilia care.
▪️Network Research and Real-World Data: Expanding registries and networks to gather data and better understand long-term outcomes for patients.
▪️Embedded Patient and Clinician Partnerships: Meaningfully engaging with patients and providers to ensure research questions are relevant to real-world needs.
This call to action is about more than just science; it’s about equity. VWD has suffered from historical underinvestment and under recognition, especially for conditions that disproportionately affect women. We believe equitable care requires equitable evidence, and VWD is too important to overlook.
Read the full commentary here.”

More posts featured in Hemostasis Today.
-
Mar 19, 2026, 18:29Rameez Ashraff: Have You Noticed Neutrophil Inclusions in a Thrombocytopenia Smear?
-
Mar 19, 2026, 18:07Leonardo Roever: A Consensus Framework for Biomarker Research and Clinical Translation in Stroke
-
Mar 19, 2026, 17:49Matteo Foschi: Breaktrough Stroke on Oral Anticoaugulants for Atrial Fibrillation
-
Mar 19, 2026, 17:30UK Haemophilia Society Continues to Empower Individuals and Families Through Advocacy, Education, and Community Support – WFH
-
Mar 19, 2026, 17:20Dimitrios Nikas: Stroke During TAVI Procedures Still Remains Noticeable High
-
Mar 19, 2026, 17:14Akinchan Bhardwaj: Differences in Bleeding Outcomes Among DOACs
-
Mar 19, 2026, 17:03How Personal Experiences Can Support Self‑Advocacy and Help Improve Healthcare Outcomes – Hemophilia Alliance
-
Mar 19, 2026, 16:54X. Long Zheng: Unpacking the Real-World Challenges of ADAMTS13 on ISTH Pulse Podcast
-
Mar 19, 2026, 16:50Zain Khalpey: Predictive Imaging and AI in Aortic Dissection Risk Assessment